Remove Bioinformatics Remove DNA Remove Research
article thumbnail

Clinical Microbiomics makes third acquisition in 18 months

Drug Discovery World

Clinical Microbiomics has acquired DNASense, a Danish microbiome clinical research organisation (CRO) specialised in long-read DNA and RNA sequencing technologies and bioinformatics. The acquisition adds long-read DNA and RNA sequencing technologies to Clinical Microbiomics’ multi-omics technologies for the microbiome field.

article thumbnail

Improving viral vector safety for gene therapies

Drug Discovery World

Following initial viral vector transduction, treated samples, typically whole blood and/or enriched cell populations, are collected and the genomic DNA is isolated. The enriched DNA is then sequenced. With this approach, high molecular weight DNA must be extracted from the treated samples, to ensure the best results.

Therapies 147
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Guide to using AAV vectors in gene therapy

Drug Discovery World

AAV is optimal for gene therapy due to its efficiency and safety in humans; however, AAV processes can present obstacles for researchers. These include automated solutions, proprietary genomics protocols, specialists to advise on global cGMP repository and logistics, plus experts to guide researchers through advanced therapy development.

Therapies 147
article thumbnail

Guide to using AAV vectors in gene therapy

Drug Discovery World

AAV is optimal for gene therapy due to its efficiency and safety in humans; however, AAV processes can present obstacles for researchers. These include automated solutions, proprietary genomics protocols, specialists to advise on global cGMP repository and logistics, plus experts to guide researchers through advanced therapy development.

Therapies 130
article thumbnail

Not all neoantigens are created equal

Drug Target Review

During the process of transformation from a normal cell into a cancer cell, a cell acquires a series of changes, or mutations, in its DNA. But DNA mutations can also result in changes to the proteins that are displayed on the surface of the cancer cell. These mutations are called clonal mutations or clonal neoantigens.

article thumbnail

Start-up hopes to boost production of viral vectors for ATMPs

Drug Discovery World

The company’s DNA-based platform is being developed to address manufacturing challenges associated with the production of recombinant adeno-associated virus (rAAV) vectors used to produce advanced therapy medicinal products (ATMPs).

article thumbnail

Drug discovery deals highlight key growth areas

Drug Discovery World

The acquisition of Olink underscores the profound impact that proteomics is having as our customers continue to advance life science research and precision medicine,” said Marc Casper, Chairman, President and Chief Executive Officer of Thermo Fisher.

DNA 130